3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 1/2
2
Phase 2
1
Status
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Carcinoma, Non-Small-Cell Lung
31
Lung Neoplasms
9
Small Cell Lung Carcinoma
7
Biliary Tract Neoplasms
7
Carcinoma, Hepatocellular
6
Urinary Bladder Neoplasms
4
Liver Neoplasms
4
Carcinoma
4
Neoplasm Metastasis
3
Breast Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma Extensive Disease
2
Recurrence
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Non-Muscle Invasive Bladder Neoplasms
2
Gallbladder Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Renal Cell
2
Urothelial Cancer
1
Sarcoma
1
Radiation Pneumonitis
1
Pancoast Syndrome
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Non Small Cell Lung Carcinoma NSCLC
1
Non Small Cell Lung Cancer NSCLC
1
Non - Small Cell Lung Cancer NSCLC
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Interventions
Mitomycin
12
Gemcitabine
9
BCG Vaccine
4
apaziquone
3
Epirubicin
3
erdafitinib
2
durvalumab
2
dodecyl maltoside
2
VB4-845
2
Docetaxel
2
viscum album peptide
1
valrubicin
1
pirarubicin
1
hydroxycamptothecinum
1
Transurethral Resection of Bladder
1
Therapeutic Uses
1
Standard of Care
1
Saline Solution
1
Radiotherapy
1
Polysorbates
1
Maintenance
1
Magnetic Resonance Spectroscopy
1
Injections
1
Cystoscopy
1
5-aminolevulinic acid hexyl ester
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Non-Muscle Invasive Bladder Neoplasms
×
durvalumab
×
Clear all
NCT05943106
2026-05-26
PATAPSCO
AstraZeneca
Phase 3
Active not recruiting
100 enrolled
NCT03528694
2026-04-14
POTOMAC
AstraZeneca
Phase 3
Active not recruiting
1,018 enrolled